Milan, Italy

Rita Nizzola

This inventor holds 1 USPTO granted patent. Top assignee: I D B Holding S.p.a.. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rita Nizzola: Innovator in Benzothiazepine Esters

Introduction

Rita Nizzola is a prominent inventor based in Milan, Italy. She has made significant contributions to the field of medicinal chemistry, particularly in the development of benzothiazepine esters. Her work focuses on creating compounds that possess therapeutic benefits while minimizing adverse effects.

Latest Patents

Rita Nizzola holds a patent for benzothiazepine esters, which are characterized by their vasodilating activity. These compounds are designed to treat arterial hypertension and improve cerebral circulation. The patent outlines a class of benzothiazepine esters that are structurally related to diltiazem, offering a promising alternative with reduced cardiodepressive effects.

Career Highlights

Throughout her career, Rita has demonstrated a commitment to advancing pharmaceutical innovations. Her research has led to the development of effective formulations that can significantly impact patient care. With one patent to her name, she continues to explore new avenues in medicinal chemistry.

Collaborations

Rita Nizzola has collaborated with notable colleagues, including Giorgio Pifferi and Salvatore Malandrino. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Rita Nizzola's contributions to the field of medicinal chemistry, particularly through her patent on benzothiazepine esters, highlight her innovative spirit and dedication to improving healthcare solutions. Her work continues to inspire future advancements in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…